BOSTON--(BUSINESS WIRE)--#DrugDiscovery--At the annual Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, BioAuxilium Research Inc., a biotech tool company focused on facilitating access to fully vali
TORONTO--(BUSINESS WIRE)--#biotech--Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, today launches Perturba Therapeutics Inc. (“Perturba”), a spin out from the Stagljar La
- Composition of matter patent strengthens proprietary position of CYB004 as a deuterated DMT compound until 2041- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focuse
WINNIPEG, Manitoba--(BUSINESS WIRE)--$FDGE #AgTech--Farmers Edge Inc. (“Farmers Edge” or the “Company”) (TSX: FDGE), a global leader in digital agriculture, today announced an agreement that will allow users of its FarmCommand® digital agricultur
Series C financing co-led by SoftBank Vision Fund 2 and RA Capital Management Proceeds will accelerate the scale-up of ReSOLVETM platform to address targets previously considered undruggable and advance the company’s small molecule pipeline across a b
Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours Treatment also demonstrated, in the high-risk group (
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2021 f
MONTREAL--(BUSINESS WIRE)--#celltherapy--Morphocell Technologies Inc. announces the development of an innovative, scalable method for generating cells that may enable future cell therapies for liver diseases and improve the way these conditions are studie
Agreement expanded to add European and Latin American markets NDA filing with US FDA for Appili’s ATI-1501 expected later this year HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appi
Flora Growth webinar with CEO Luis Merchan on February 11th at 1 pm EST where he will discuss the Company’s perspective on CBD and the Global Market. Register here. MIAMI & TORONTO--(BUSINESS WIRE)--Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the
Shelley King is one of Atlantic Business Magazine’s Top 50 CEOs of 2022! Her award-winning status was announced May 12th at a red-carpet gala in Halifax.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.